AstraZeneca Posts Positive Trial Results
AstraZeneca's ALXN1850 shows favourable safety profile and meets key secondary endpoint in bone health in Mulberry Phase III trial
ALXN1850 Showed Favourable Safety Profile Study Met Key Secondary Endpoint In Bone Health